- Home
- IMPP vs CSBR Comparison
IMPP vs CSBR Comparison
Compare IMPP & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- CSBR
- Stock Information
- Founded
- IMPP 1981
- CSBR 1985
- Country
- IMPP Greece
- CSBR United States
- Employees
- IMPP N/A
- CSBR N/A
- Industry
- IMPP Marine Transportation
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMPP Consumer Discretionary
- CSBR Health Care
- Exchange
- IMPP Nasdaq
- CSBR Nasdaq
- Market Cap
- IMPP 103.9M
- CSBR 123.2M
- IPO Year
- IMPP N/A
- CSBR 1986
- Fundamental
- Price
- IMPP $2.97
- CSBR $6.51
- Analyst Decision
- IMPP
- CSBR Strong Buy
- Analyst Count
- IMPP 0
- CSBR 1
- Target Price
- IMPP N/A
- CSBR $12.00
- AVG Volume (30 Days)
- IMPP 132.8K
- CSBR 43.3K
- Earning Date
- IMPP 08-26-2025
- CSBR 09-10-2025
- Dividend Yield
- IMPP N/A
- CSBR N/A
- EPS Growth
- IMPP N/A
- CSBR N/A
- EPS
- IMPP 1.21
- CSBR 0.33
- Revenue
- IMPP $138,368,325.00
- CSBR $56,944,000.00
- Revenue This Year
- IMPP $8.79
- CSBR $9.30
- Revenue Next Year
- IMPP $40.11
- CSBR $31.17
- P/E Ratio
- IMPP $2.45
- CSBR $19.76
- Revenue Growth
- IMPP N/A
- CSBR 13.54
- 52 Week Low
- IMPP $2.12
- CSBR $3.60
- 52 Week High
- IMPP $4.55
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- IMPP 41.40
- CSBR 44.47
- Support Level
- IMPP $2.92
- CSBR $6.07
- Resistance Level
- IMPP $3.06
- CSBR $7.00
- Average True Range (ATR)
- IMPP 0.15
- CSBR 0.43
- MACD
- IMPP -0.02
- CSBR 0.04
- Stochastic Oscillator
- IMPP 17.50
- CSBR 57.62
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.